Senovac
Senovac has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest paper, May 20, 2026: “Senescent Cell Derived Artificial Vesicle-Based Senolytic Sonovaccine Platform with Augmented Lymph Node Delivery and Antigen Cross-Presentation Efficacy”.
1 paper studies it2 findingsUpdated
At a glance
The findings reach mice, none yet in people. 1 lab in 1 country.
None of its findings points the other way.
- 1 lab in 1 country
- Funders: Fourth Military Medical University and 1 more
- Animals1
What did studies of senovac find?
2Studies of senovac measured 2 outcomes: atherosclerosis and senescent cells.
Atherosclerosis
downin mice1
1 study
Atherosclerosis
downin mice1
Senovac decreases atherosclerosis in ApoE-/- mouse model of atherosclerosis.
“effectively cleared plaque senescent cells, attenuated disease progression”
Animalsin ApoE-/- mouse model of atherosclerosis
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Senescent cells
downin mice1
1 study
Senescent cells
downin mice1
Senovac decreases senescent cells in ApoE-/- mouse model of atherosclerosis.
“effectively cleared plaque senescent cells, attenuated disease progression”
Animalsin ApoE-/- mouse model of atherosclerosis
Advanced science (Weinheim, Baden-Wurttemberg, Germany)